It may seem ironic to many that a tobacco company is buying a respiratory specialist biotech but Philip Morris International (PMI) is not expecting any backlash for its planned £1.04bn ($1.44bn) acquisition of the UK's Vectura Group plc, insisting that the purchase is a key component of a shift from selling cigarettes to becoming "a broader healthcare and wellness company."
Eyebrows were raised when it was announced on 9 July that PMI had outbid private equity group Carlyle to get...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
